BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-t...
Saved in:
Main Authors: | Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2024-08-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | https://www.mjhid.org/mjhid/article/view/5793 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
by: Jin Yin, et al.
Published: (2024-12-01) -
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01) -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
by: Ugo Testa, et al.
Published: (2024-01-01) -
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01) -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
by: Ugo Testa, et al.
Published: (2024-02-01)